Effect of Injection Site on the Relative Bioavailability of Single Dose of LY3209590 and Evaluation of Absolute Bioavailability of LY3209590 in Healthy Participants
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Insulin efsitora alfa (Primary) ; Insulin efsitora alfa (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 May 2023 Planned End Date changed from 6 Jun 2023 to 27 Jun 2023.
- 08 May 2023 Planned primary completion date changed from 6 Jun 2023 to 27 Jun 2023.